about
Effect of mesenchymal stem cells on Sjögren-like mice and the microRNA expression profiles of splenic CD4+ T cellsEnvironmental Basis of Autoimmunity.Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome.SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome.Treatment of xerostomia and hyposalivation in the elderly: A systematic review.Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.Transforming growth factor β activated kinase 1: a potential therapeutic target for rheumatic diseases.Investigational drugs in dry eye disease.Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.Analysis of the Pathogenic Factors and Management of Dry Eye in Ocular Surface DisordersFirst-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjögren's syndrome.A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [14 C]Seletalisib (UCB5857) in Healthy Subjects.Defective Early B Cell Tolerance Checkpoints in Sjögren's Syndrome Patients.Primary Sjögren's Syndrome Adversely Affects the Female Sexual Function Assessed by the Female Sexual Function Index: A Case-Control Study
P2860
Q33744508-B96BBE73-72C4-4D28-8AC9-A7C1ED952328Q35638839-E4233258-49C6-4E3E-8C95-4B994AB548CAQ37542648-2C1025E5-FF78-40A3-9039-6184C348062AQ37587370-69634489-CC9C-4AD1-99F2-1E8FC4041291Q38794316-7B0E1422-133D-4161-916B-1B6EDD2DE6E5Q38905170-C0D215F6-AB28-4698-95FF-C587218FE1ABQ38934371-D301C727-9B8D-4FA6-975A-2E99F8D98929Q38984001-20BEFC82-6F6C-4A4D-B526-8E059CE50192Q40383414-347D7A97-D9FD-4B07-9278-E1AC81CE7297Q41574217-72A02322-36D5-4755-84A4-E182780A39B4Q41991078-6C49D5D0-2B73-4252-A6E8-CBD89D00B10FQ46347777-16E4CD0F-FF7D-4746-AC26-520CE844F54BQ50560944-5F4E2105-E6C6-426C-8B86-F530C5E2F852Q50892871-6203AE5F-54B1-432B-97CF-1C56A72B8BA9Q58133977-229049C6-D03C-46C9-913F-F509DC94DAF8
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Biologic treatment in Sjögren's syndrome.
@en
type
label
Biologic treatment in Sjögren's syndrome.
@en
prefLabel
Biologic treatment in Sjögren's syndrome.
@en
P2860
P356
P1433
P1476
Biologic treatment in Sjögren's syndrome
@en
P2093
Pablo Ruiz Sada
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEU417
P577
2014-10-22T00:00:00Z